Cardiovascular and Metabolism

Novartis is focused on improving the lives of the hundreds of millions of people with cardiovascular and metabolic diseases. As a global leader in cardiovascular and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat high blood pressure  and diabetes - both major public health issues.

The portfolio includes the following treatments for high blood pressure:

• Diovan (valsartan), the world's most-prescribed angiotensin receptor blocker
• Co-Diovan/Diovan HCT (valsartan and hydrochlorothiazide)
• Exforge (amlodipine and valsartan), a single pill combining two leading high blood pressure medicines
• Tekturna/Rasilez (aliskiren), the first and only approved direct renin inhibitor

Top products also include cholesterol-lowering agent Lescol (fluvastatin sodium) and the following treatments for type 2 diabetes:

• Galvus (vildagliptin), a novel DPP-4 inhibitor
• Eucreas (vildagliptin and metformin)

Learn more about our products for cardiovascular and metabolic conditions